Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted drug combo outsmart brain lymphoma?

NCT ID NCT05036577

NEW Completed Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This early-stage trial is testing whether adding the targeted drug orelabrutinib to a standard chemotherapy regimen can safely treat newly diagnosed primary central nervous system lymphoma (PCNSL), a rare type of lymphoma that starts in the brain or spinal cord. The study will enroll about 13 people with this condition who have not yet received treatment. The main goals are to find the safest dose of orelabrutinib when combined with the other drugs and to see how well the combination works at shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Orelabrutinib combined with rituximab, methotrexate, and dexamethasone
What this could lead to
If successful, this combination could offer a new, more effective treatment option for primary central nervous system lymphoma, potentially improving outcomes without the need for whole-brain radiation.
What could go wrong
This is a small, early-phase dose-finding study, so safety and the best dose are still being determined. The combination may cause significant side effects, and it is too soon to know if it will be more effective than current standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

  • Department of Hematology, Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.